EuroBiotech: More Articles of Note


> Genfit offloaded the Chinese rights to NASH prospect elafibranor to Terns Pharmaceuticals for $35 million (€31 million) upfront. The deal is worth up to $193 million more in milestones. Statement 

> Boehringer Ingelheim made a milestone payment to Oxford BioTherapeutics after it advanced an oncology drug candidate. Release 

> Vesalius Biocapital closed its third life sciences fund at €120 million. The VC shop had aimed to raise $150 million and close the fund last year. Statement 


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> C4X Discovery teamed up with PhoreMost to access technology to support its Parkinson’s disease drug discovery activities. Release 

> Poxel and Sumitomo Dainippon posted top-line data from a phase 3 trial of imeglimin in Type 2 diabetes. The trial met its primary endpoint. Statement 

> Allergy Therapeutics secured a $7.6 million settlement through litigation against Inflamax Research. The case centered on whether a phase 2 allergy trial was performed properly. Release 

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.